ArrowMark Colorado Holdings’s Relay Therapeutics RLAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.38M Hold
541,124
0.14% 170
2025
Q4
$4.58M Hold
541,124
0.1% 203
2025
Q3
$2.82M Hold
541,124
0.05% 217
2025
Q2
$1.87M Hold
541,124
0.03% 232
2025
Q1
$1.42M Hold
541,124
0.02% 239
2024
Q4
$2.23M Hold
541,124
0.03% 227
2024
Q3
$3.83M Hold
541,124
0.05% 205
2024
Q2
$3.53M Sell
541,124
-3,464,046
-86% -$23.7M 0.04% 225
2024
Q1
$33.2M Buy
4,005,170
+90,924
+2% +$887K 0.37% 72
2023
Q4
$43.1M Buy
3,914,246
+103,667
+3% +$875K 0.48% 63
2023
Q3
$32M Buy
3,810,579
+391,910
+11% +$4.21M 0.39% 75
2023
Q2
$42.9M Buy
3,418,669
+748,472
+28% +$9.31M 0.47% 69
2023
Q1
$44M Sell
2,670,197
-16,514
-0.6% -$296K 0.5% 60
2022
Q4
$40.1M Buy
2,686,711
+174,243
+7% +$3.34M 0.48% 66
2022
Q3
$56.2M Sell
2,512,468
-328,205
-12% -$7.2M 0.69% 48
2022
Q2
$47.6M Buy
2,840,673
+815,559
+40% +$17.5M 0.54% 61
2022
Q1
$60.6M Sell
2,025,114
-8,210
-0.4% -$199K 0.53% 58
2021
Q4
$62.4M Buy
2,033,324
+1,590,591
+359% +$50.3M 0.5% 61
2021
Q3
$14M Buy
442,733
+70,538
+19% +$2.37M 0.11% 155
2021
Q2
$13.6M Buy
372,195
+32,759
+10% +$1.08M 0.1% 164
2021
Q1
$11.7M Sell
339,436
-841
-0.2% -$36.5K 0.09% 181
2020
Q4
$14.1M Sell
340,277
-4,677
-1% -$211K 0.11% 144
2020
Q3
$14.7M Buy
+344,954
New +$13.2M 0.14% 120

Other funds holding RLAY

ArrowMark Colorado Holdings's RLAY Position: Q1 2026 in Review

ArrowMark Colorado Holdings held its Relay Therapeutics (RLAY) position steady in Q1 2026 at 541,124 shares worth $5.38M. The position accounts for 0.14% of the portfolio, ranked #170.

ArrowMark Colorado Holdings first reported a position in RLAY in Q3 2020 and has held it in 23 quarters since. The position peaked at $62.4M in Q4 2021. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • ArrowMark Colorado Holdings held 541,124 shares of Relay Therapeutics worth $5.38M as of Q1 2026.
  • ArrowMark Colorado Holdings left its Relay Therapeutics share count unchanged in Q1 2026.
  • Relay Therapeutics made up 0.14% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #170 holding.
  • ArrowMark Colorado Holdings first reported a position in Relay Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • ArrowMark Colorado Holdings's Relay Therapeutics position peaked at $62.4M in Q4 2021.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.